2022
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2022, 1-10. DOI: 10.1002/9781119000822.hfcm083.pub2.Peer-Reviewed Original ResearchPeptide receptor radiotherapyMultiple endocrine neoplasiaDiffuse neuroendocrine systemClinical featuresHepatic metastasesNeuroendocrine tumorsGastroenteropancreatic systemNeuroendocrine systemInformed clinical careUnique clinical syndromeOngoing clinical trialsAbsence of symptomsCancer registry dataUnexplained incidenceReceptor radiotherapyClinical presentationRandomized trialsTherapeutic optionsClinical syndromeMultiple myelomaSomatostatin analoguesSpecific therapyRecent trialsSurvival resultsClinical trials
2017
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2017, 1-12. DOI: 10.1002/9781119000822.hfcm083.ChaptersDiffuse neuroendocrine systemClinical featuresNeuroendocrine tumorsGastroenteropancreatic systemProgression-free survival benefitNeuroendocrine systemMultiple endocrine neoplasia syndromeInformed clinical careUnique clinical syndromeFive-year survivalOngoing clinical trialsAbsence of symptomsCancer registry dataEndocrine neoplasia syndromeUnexplained incidenceSurvival benefitClinical presentationHepatic metastasesClinical syndromeMultiple myelomaSurvival resultsClinical trialsRegistry dataNeoplasia syndromeClinical care
2000
Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
Abshire T, Brackmann H, Scharrer I, Hoots K, Gazengel C, Powell J, Gorina E, Kellermann E, Vosburgh E. Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. Thrombosis And Haemostasis 2000, 83: 811-816. PMID: 10896230, DOI: 10.1055/s-0037-1613925.Peer-Reviewed Original ResearchConceptsRFVIII-FSHome therapyAdverse eventsPharmacokinetic profileHemophilia ADrug-related adverse eventsRecombinant factor VIII productsIntermittent chest painFactor replacement therapyTreatment of bleedsSevere haemophilia AFirst clinical trialFactor VIII productsExcellent hemostatic controlSignificant adverse effectsFull-length rFVIIIChest painReplacement therapyClinical trialsViral inactivation stepsHemostatic controlExposure daysPatientsFactor VIIITherapy
1992
Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.
Vosburgh E. Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. Leukemia 1992, 6: 608-10. PMID: 1602800.Peer-Reviewed Case Reports and Technical NotesConceptsPulmonary leukostasisComplete remissionFirst relapseStandard induction chemotherapyRetinoic acid syndromeRetinoic acidAcute promyelocytic leukemiaAcute promyelocytic leukemia cellsTrans retinoic acidInduction chemotherapyResistant diseaseSignificant leukocytosisClinical trialsLeukostasisPromyelocytic leukemiaPromyelocytic leukemia cellsMature neutrophilsPatientsLeukemia cellsRelapseHigh rateOverall toxicityDe novoRemissionLeukocytosis